Lupin is a global pharmaceutical company offering a wide range of products including branded and generic formulations, Active Pharmaceutical Ingredients (APIs), biotechnology products and speciality medicines.
With a presence in over 100 countries, Lupin offers high-quality yet affordable medicines for some of the most chronic diseases addressing unmet needs in many parts of the world.
Novel drug discovery and development in oncology, immunology and metabolic disorders, partnering with global pharma companies like Abbvie and Boehringer in novel drug development.
Lupin has a significant presence in the therapy areas of Gynaecology, Cardiovascular, Diabetes, Asthma, Paediatrics, Central Nervous System (CNS), Gastrointestinal (GI), Anti-Infective (AI) and Non-Steroidal
Anti-Inflammatory Drugs (NSAIDs).
1. Lupin Ltd. Investor presentation FY 2021-22. https://www.lupin.com/wp-content/uploads/2022/05/lupin-investor-presentation-fy2021-22.pdf. Accessed: Jan 2023.
UK-LUP-2208-00003 DOP: September 2022